Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 31, Issue 1, Pages 24-38
Publisher
Springer Nature
Online
2017-11-17
DOI
10.1038/modpathol.2017.104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features
- (2017) Emily A Merkel et al. LABORATORY INVESTIGATION
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma
- (2016) L Manfredi et al. ACTA DERMATO-VENEREOLOGICA
- D03*Liver resection for colorectal liver metastases: can we cure our patients?
- (2016) D. Ribero et al. ANNALS OF ONCOLOGY
- B-Raf Inhibition in the Clinic: Present and Future
- (2016) Warren Fiskus et al. Annual Review of Medicine
- Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
- (2016) Laura Schirosi et al. BMC CANCER
- BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
- (2016) Emilia Hugdahl et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
- (2016) Liqiang Xi et al. CLINICAL CANCER RESEARCH
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies
- (2016) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
- (2016) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature
- (2016) Muhammad Ahmed Farooq Anwar et al. JOURNAL OF SURGICAL RESEARCH
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Coming of age: ten years of next-generation sequencing technologies
- (2016) Sara Goodwin et al. NATURE REVIEWS GENETICS
- The state of melanoma: challenges and opportunities
- (2016) Glenn Merlino et al. Pigment Cell & Melanoma Research
- Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
- (2016) Mack Y. Su et al. PLOS MEDICINE
- Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma
- (2016) Guo Chen et al. JAMA Oncology
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
- (2015) Gatien Moriceau et al. CANCER CELL
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
- (2015) A. Santiago-Walker et al. CLINICAL CANCER RESEARCH
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients
- (2015) Sharon K. Huang et al. Molecular Oncology
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- (2015) M. R. Girotti et al. Cancer Discovery
- BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
- (2015) Caterina Chiappetta et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- BRAFV600EProtein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
- (2015) Hanna Eriksson et al. JAMA Dermatology
- Melanoma
- (2015) Dirk Schadendorf et al. Nature Reviews Disease Primers
- The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
- (2014) Boris C. Bastian Annual Review of Pathology-Mechanisms of Disease
- Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations
- (2014) Michaela Angelika Ihle et al. BMC CANCER
- The MAPK pathway across different malignancies: A new perspective
- (2014) Mauricio Burotto et al. CANCER
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach
- (2014) Joshua R. Bradish et al. HUMAN PATHOLOGY
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the VE1 immunostain for theBRAFV600E mutation in melanoma
- (2014) Michelle V. Pearlstein et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy
- (2014) Joshua R Bradish et al. MODERN PATHOLOGY
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
- (2014) Alain R Thierry et al. NATURE MEDICINE
- Pragmatic issues in biomarker evaluation for targeted therapies in cancer
- (2014) Armand de Gramont et al. Nature Reviews Clinical Oncology
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- High-Resolution Melting Analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis
- (2014) Dong Chen et al. Scientific Reports
- Fundamentals of Pyrosequencing
- (2013) Colleen T. Harrington et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Detection ofBRAFp.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility
- (2013) Cristi Marin et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
- (2013) L Heinzerling et al. BRITISH JOURNAL OF CANCER
- Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations
- (2013) Joshua R Bradish et al. Future Oncology
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of BRAF V600 Mutations in Metastatic Melanoma
- (2013) Kevin Qu et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib
- (2013) Fernando Lopez-Rios et al. PLoS One
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
- (2012) Georgina V. Long et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of BRAF p.V600E Mutations in Melanomas
- (2012) Emeline Colomba et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
- (2012) Molly Yancovitz et al. PLoS One
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Immunohistochemistry for Biomarker Assessment—Can It Compete with Other Technologies?
- (2011) Robert W. Dunstan et al. TOXICOLOGIC PATHOLOGY
- Validation of Analytic Methods for Biomarkers Used in Drug Development
- (2008) C. H. Chau et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started